Resmed Inc (RMD) Stock Price, Quote & News

Company Profile

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry,...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 858-836-5000

Website: www.resmed.com

Address:

9001 Spectrum Center Boulevard, San Diego, United States

EddieHayes Jul. 14 at 2:16 PM

The broader market maintains historically elevated metrics, with the S&P 500 average P/E ratio tracking near 25.6. High-conviction stock picking requires isolating relative value. The following assets present compelling alternative valuation structures: $ZTS P/E 12.51x $RMD 19.6x $NFLX 23.22x $PGR 11.69x $KNSL 14.92x BRO 19.22x CME 19.33x If you want to see the high-conviction stocks I’m watching, my full portfolio, and every trade I make… Head to my profile.

0 · Reply

stockro1 Jul. 13 at 2:44 PM

$IXHL $RMD still find this interesting given Goldman Sachs continued presence on the L2…https://www.gurufocus.com/news/8941991/resmed-rmd-added-to-goldman-sachs-apac-conviction-list

0 · Reply

SBL71 Jul. 13 at 11:50 AM

$RMD Apnimed IPO could be happening soon. It’s getting closer.

1 · Reply

jjjetplane Jul. 10 at 7:28 PM

Doubled $MSFT and $NVDA positions today. Started $PODD and $RMD

0 · Reply

IN0V8 Jul. 10 at 3:12 PM

$RMD Jefferies cuts target price to $225 from $240

0 · Reply

Rvvrn9 Jul. 7 at 11:56 AM

$IXHL Three choices, $RMD buy before DReAMzz, pay 3× after, or risk losing it to someone like Johnson & Johnson. Get your sh*t together and let’s goooo!!!

2 · Reply

ETAlpha Jul. 6 at 9:42 PM

Relative Volume Scanner Highlights for 7/6. Capital continues to rotate heavily into Health Technology, driving significant liquidity into the sector. Here are the top-performing structural setups: $YDES - 37.5x $CRNX -2.8x $RMD- 2.0x $LMND - 1.7x $RXRX - 1.6x While price shows the direction, volume measures the conviction behind the move. These massive volume spikes indicate strong institutional footprint-keep them on your watchlist for potential momentum follow-through. "I don’t post noise. Only conviction setups, real positions, real trades. Profile has it all."

0 · Reply

DonCorleone77 Jul. 2 at 3:01 AM

$RMD ResMed added to APAC Conviction List at Goldman Sachs Goldman Sachs analysts added ResMed to the firm's APAC Conviction List as part of its monthly update. The firm expects continuous airway pressure therapy patient growth for the company. It keeps a Buy rating on the shares with a A$46.70 price target.

1 · Reply

BillionerOfKing Jun. 30 at 1:00 AM

$RMD Current Stock Price: $198.47 Contracts to trade: $200.0 RMD Jul 17 2026 Call Entry: $2.95 Exit: $5.43 ROI: 84% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

BillionerOfKing Jun. 22 at 5:29 PM

$RMD Current Stock Price: $189.04 Contracts to trade: $190.0 RMD Jul 17 2026 Call Entry: $5.40 Exit: $10.49 ROI: 94% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ResMed price target lowered to $220 from $235 at Mizuho

2026-07-12T23:20:07.000Z - 2 days ago

ResMed downgraded to Neutral from Buy at Citi

2026-07-10T13:10:28.000Z - 5 days ago

ResMed price target lowered to $225 from $240 at Jefferies

2026-07-08T11:45:32.000Z - 7 days ago

ResMed price target lowered to $276 from $321 at RBC Capital

2026-07-08T10:25:21.000Z - 7 days ago

ResMed price target lowered to $225 from $227 at Wells Fargo

Jul 7, 2026, 6:07 PM EDT - 7 days ago

ResMed to sell software business MatrixCare for $490 million

2026-07-07T21:10:11.000Z - 8 days ago

Frazier to acquire MatrixCare from ResMed, terms not disclosed

Jul 7, 2026, 5:06 PM EDT - 8 days ago

Frazier Healthcare Partners Announces Definitive Agreement to Acquire MatrixCare

2026-07-07T20:35:31.000Z - 8 days ago

ResMed to sell MatrixCare business to Frazier Healthcare, terms undisclosed

Jul 7, 2026, 4:30 PM EDT - 8 days ago

Resmed Announces Agreement to Sell MatrixCare Business

Jul 7, 2026, 7:00 AM EDT - 8 days ago

ResMed Slides: Divestiture of MatrixCare presentation

2026-07-01T23:15:24.000Z - 13 days ago

ResMed added to APAC Conviction List at Goldman Sachs

Jun 30, 2026, 4:30 PM EDT - 15 days ago

Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026

2026-06-22T09:45:57.000Z - 23 days ago

ResMed price target lowered to $266 from $290 at KeyBanc

2026-06-17T09:35:08.000Z - 4 weeks ago

ResMed downgraded to Equal Weight from Overweight at Morgan Stanley

2026-06-15T10:21:45.000Z - 4 weeks ago

ResMed price target lowered to $270 from $340 at Citi

Jun 3, 2026, 7:40 AM EDT - 6 weeks ago

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

Jun 2, 2026, 5:40 PM EDT - 6 weeks ago

ResMed Transcript: 46th Annual William Blair Growth Stock Conference

Jun 2, 2026, 5:40 PM EDT - 6 weeks ago

ResMed Slides: 46th Annual William Blair Growth Stock Conference

Jun 1, 2026, 4:05 PM EDT - 6 weeks ago

Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

May 19, 2026, 4:05 PM EDT - 2 months ago

Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference

2026-05-19T13:10:59.000Z - 2 months ago

ResMed, Oura partner to expand access to sleep health education

May 19, 2026, 9:00 AM EDT - 2 months ago

Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care

2026-05-01T14:35:07.000Z - 2 months ago

ResMed price target lowered to $225 from $254 at Baird

2026-05-01T11:18:33.000Z - 2 months ago

ResMed price target lowered to $235 from $265 at Stifel

Apr 30, 2026, 6:21 PM EDT - 2 months ago

ResMed beats quarterly profit estimates, names new CFO

Apr 30, 2026, 4:30 PM EDT - 2 months ago

ResMed Earnings Call Transcript: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

ResMed Earnings release: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

ResMed Slides: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

ResMed Quarterly report: Q3 2026

Apr 30, 2026, 4:10 PM EDT - 2 months ago

Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor

Apr 30, 2026, 4:05 PM EDT - 2 months ago

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026

Apr 1, 2026, 4:05 PM EDT - 3 months ago

Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026

Mar 3, 2026, 3:00 AM EST - 4 months ago

Resmed's Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach

Feb 25, 2026, 12:56 PM EST - 5 months ago

ResMed At $250: Missed Opportunity Or A Trap In The Making?

Feb 24, 2026, 9:00 AM EST - 5 months ago

Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana

Feb 3, 2026, 12:29 AM EST - 5 months ago

Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge

NVO

Jan 29, 2026, 4:41 PM EST - 5 months ago

ResMed beats quarterly profit estimates on strong demand for its sleep devices

Jan 29, 2026, 4:30 PM EST - 5 months ago

ResMed Earnings Call Transcript: Q2 2026

Jan 29, 2026, 4:30 PM EST - 5 months ago

ResMed Quarterly report: Q2 2026

Jan 29, 2026, 4:30 PM EST - 5 months ago

ResMed Earnings release: Q2 2026

Jan 29, 2026, 4:30 PM EST - 5 months ago

ResMed Slides: Q2 2026

Jan 29, 2026, 4:05 PM EST - 5 months ago

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026

Jan 12, 2026, 1:30 PM EST - 6 months ago

ResMed Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 1:30 PM EST - 6 months ago

ResMed Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:05 PM EST - 6 months ago

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026

Dec 18, 2025, 4:05 PM EST - 7 months ago

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Dec 8, 2025, 9:00 AM EST - 7 months ago

Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy

Nov 24, 2025, 2:15 PM EST - 8 months ago

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

IDXX

Nov 19, 2025, 6:00 PM EST - 8 months ago

ResMed Transcript: AGM 2025

Oct 30, 2025, 4:30 PM EDT - 9 months ago

ResMed Earnings Call Transcript: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 9 months ago

ResMed Quarterly report: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 9 months ago

ResMed Earnings release: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 9 months ago

ResMed Slides: Q1 2026

Oct 30, 2025, 4:05 PM EDT - 9 months ago

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026

Oct 9, 2025, 4:05 PM EDT - 9 months ago

Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025

Oct 2, 2025, 8:00 AM EDT - 10 months ago

ResMed Proxy statement: Proxy Filing

Oct 2, 2025, 8:00 AM EDT - 10 months ago

ResMed Proxy statement: Proxy Filing

Sep 23, 2025, 8:20 AM EDT - 10 months ago

ResMed Transcript: Bank of America Global Healthcare Conference 2025

Sep 18, 2025, 7:00 AM EDT - 10 months ago

ResMed Slides: Corporate Presentation

Sep 16, 2025, 4:05 PM EDT - 10 months ago

Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025

Sep 12, 2025, 7:00 AM EDT - 10 months ago

ResMed Slides: Sustainability Presentation

Sep 8, 2025, 9:00 PM EDT - 11 months ago

The sleep economy is 'having a moment', says medical equipment firm Resmed

Sep 3, 2025, 4:15 PM EDT - 11 months ago

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority

Aug 27, 2025, 9:00 AM EDT - 11 months ago

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds

Aug 18, 2025, 4:15 PM EDT - 11 months ago

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio

Jul 31, 2025, 4:53 PM EDT - 1 year ago

Resmed beats quarterly profit estimates on strong demand for sleep devices

Jul 31, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings Call Transcript: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

ResMed Annual report: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings release: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

ResMed Slides: Q4 2025

Jul 31, 2025, 4:05 PM EDT - 1 year ago

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

Jul 30, 2025, 6:08 AM EDT - 1 year ago

Spot Outliers Like ResMed Early with Money Flows

Jul 1, 2025, 4:05 PM EDT - 1 year ago

Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

May 15, 2025, 9:00 AM EDT - 1 year ago

Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025

May 1, 2025, 9:00 AM EDT - 1 year ago

Resmed Acquires VirtuOx

Apr 23, 2025, 5:08 PM EDT - 1 year ago

ResMed slightly beats quarterly profit estimates on sleep devices demand

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings Call Transcript: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Quarterly report: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings release: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Slides: Q3 2025

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

Apr 21, 2025, 5:00 PM EDT - 1 year ago

Resmed Names Salli Schwartz as Chief Investor Relations Officer

Apr 3, 2025, 9:00 AM EDT - 1 year ago

Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

Mar 19, 2025, 8:00 AM EDT - 1 year ago

New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

Mar 11, 2025, 9:00 AM EDT - 1 year ago

Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

Feb 26, 2025, 3:00 AM EST - 1 year ago

ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

Feb 11, 2025, 4:30 AM EST - 1 year ago

Jan De Witte joins GHO Capital as Operating Partner

IART

Jan 30, 2025, 5:21 PM EST - 1 year ago

ResMed beats quarterly profit estimates on demand for sleep disorder devices

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Earnings Call Transcript: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Earnings release: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Quarterly report: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Slides: Q2 2025

Jan 30, 2025, 4:05 PM EST - 1 year ago

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025

Jan 13, 2025, 6:00 PM EST - 1 year ago

ResMed Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 6:00 PM EST - 1 year ago

ResMed Slides: FY 2025

Jan 9, 2025, 4:05 PM EST - 1 year ago

ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025

Jan 6, 2025, 4:05 PM EST - 1 year ago

ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 2:59 PM EST - 1 year ago

Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound

INSP LLY

Dec 4, 2024, 4:13 AM EST - 1 year ago

Canada Sleep Apnea Devices Market Research Report 2024: Opportunities and Forecasts to 2029 Featuring Braebon Medical, VitalAire, FPM Solutions, SomnoMed, and ResMed

EddieHayes Jul. 14 at 2:16 PM

0 · Reply

stockro1 Jul. 13 at 2:44 PM

$IXHL $RMD still find this interesting given Goldman Sachs continued presence on the L2…https://www.gurufocus.com/news/8941991/resmed-rmd-added-to-goldman-sachs-apac-conviction-list

0 · Reply

SBL71 Jul. 13 at 11:50 AM

$RMD Apnimed IPO could be happening soon. It’s getting closer.

1 · Reply

jjjetplane Jul. 10 at 7:28 PM

Doubled $MSFT and $NVDA positions today. Started $PODD and $RMD

0 · Reply

IN0V8 Jul. 10 at 3:12 PM

$RMD Jefferies cuts target price to $225 from $240

0 · Reply

Rvvrn9 Jul. 7 at 11:56 AM

$IXHL Three choices, $RMD buy before DReAMzz, pay 3× after, or risk losing it to someone like Johnson & Johnson. Get your sh*t together and let’s goooo!!!

2 · Reply

ETAlpha Jul. 6 at 9:42 PM

0 · Reply

DonCorleone77 Jul. 2 at 3:01 AM

1 · Reply

BillionerOfKing Jun. 30 at 1:00 AM

0 · Reply

BillionerOfKing Jun. 22 at 5:29 PM

0 · Reply

StrayTrader Jun. 17 at 8:30 PM

$RMD Morgan Stanley killed it … but it is true that Philips Respironics will likely be back in 2027. Still, this was too much today, and probably worth adding some.

0 · Reply

anachartanalyst Jun. 17 at 2:01 PM

$RMD https://anachart.com/wp-content/uploads/2026/06/1781704878_soc-img.jpg

0 · Reply

theonetrue Jun. 17 at 1:15 PM

$FIG $LZB $REXR $RMD $SPCX not helpful

0 · Reply

theflynews Jun. 17 at 1:14 PM

Pre-Market Fly By for Wednesday, June 17th: Breaking Stock Market News $SPCX $LZB $RMD $REXR $FIG

0 · Reply

ripster47 Jun. 17 at 11:22 AM

$RMD | Morgan Stanley Downgrades ResMed to Equalweight with $230 PT on Margin Pressures and Competitive Re-entry Morgan Stanley stays cautious as component cost headwinds and Philips’ re-entry into the US device market temper upside. 🔹 Follow @tenet_research for more analyst insights on other tickers.

0 · Reply

theflynews Jun. 17 at 9:46 AM

ResMed just downgraded at Morgan Stanley, here's why - $RMD - https://thefly.com/RMD

0 · Reply

StrayTrader Jun. 8 at 2:02 PM

$RMD whether reality or not, the retatrutide news from Lilly is going to put a lid on ResMed with the narrative that obesity and sleep apnea will be greatly reduced

0 · Reply

RollTheDice369 Jun. 8 at 8:46 AM

$LLY Bye bye $RMD

0 · Reply

StrayTrader Jun. 5 at 2:33 PM

$RMD hopefully clears 200 today and stays there. On the numbers, it should not in any case be less than 200. And no, neither GLP-1’s nor some pill with cannabinoids and breathing stabilizers is going to make any difference.

0 · Reply

KopOut Jun. 5 at 2:10 PM

$RMD started position at 198.43

0 · Reply

StrayTrader Jun. 5 at 2:54 AM

$RMD belongs back over $200 … maybe soon

0 · Reply

ConsistentSpike Jun. 4 at 2:20 PM

$RMD https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-and-oura-link-consumer-sleep-data-to-clinical-care-pa

0 · Reply

Market Cap	28.79B
Revenue (ttm)	5.15B
Net Income (ttm)	1.40B
EPS (ttm)	N/A
PE Ratio	18.93
Forward PE	16.84
Profit Margin	27.22%
Debt to Equity Ratio	0.06

Volume	1,208,781
Avg Vol	1,637,934
Day's Range	N/A - N/A
Shares Out	145.06M
Stochastic %K	9%
Beta	0.78
Analysts	Sell
Price Target	$243.78